Search

Your search keyword '"Butini, L"' showing total 141 results

Search Constraints

Start Over You searched for: Author "Butini, L" Remove constraint Author: "Butini, L"
141 results on '"Butini, L"'

Search Results

1. Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort

3. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

4. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

5. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

6. Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

7. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus

12. Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe

13. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART

14. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

15. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

16. Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis

17. No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

18. Low Rate of Virological Failure and Maintenance of Susceptibility to HIV-1 Protease Inhibitors with First-Line Lopinavir/Ritonavir-Based Antiretroviral Treatment in Clinical Practice

19. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting

20. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

21. Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART

22. Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

23. A novel methodology for large-scale phylogeny partition

24. A novel methodology for large-scale phylogeny partition

25. Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study

26. A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen

27. IMMUNOLOGICAL EFFICACY OF MARAVIROC (MVC) AS INTENSIFICATION STRATEGY IN HIV-INFECTED PATIENTS (PTS) FAILING CD4 RECOVERY ON VIROLOGICALLY-SUPPRESSIVE HAART

29. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice

30. Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder (INR) HIV-1-infected patients treated with HAART

33. A Prognostic Model for Estimating the Time to Virologic Failure in HIV-1 Infected Patients Undergoing a New Combination Antiretroviral Therapy Regimen

34. Predictors of Costs of Antiretrovirals for HIV Infection in Italy: A Multicentric Retrospection in 2012

50. Theme 5: genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.

Catalog

Books, media, physical & digital resources